For the year ending 2025-12-31, MCRB had $14,973K increase in cash & cash equivalents over the period. $865K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 5,696 |
| Stock-based compensation expense | 10,840 |
| Depreciation and amortization expense | 4,133 |
| Non-cash operating lease cost | 8,420 |
| Net (accretion) amortization of (discounts) premiums on investments | 0 |
| Gain on sale of vowst business, net of transaction costs | 0 |
| Amortization of debt issuance costs | 0 |
| Loss associated with extinguishment of debt | 0 |
| (gain)/loss on disposal of fixed assets | 192 |
| Impairment of long-lived assets | 0 |
| Change in fair value of warrant liabilities | 0 |
| Collaboration (profit) loss sharing - related party | 0 |
| Accounts receivable due from spn - related party | -1,708 |
| Prepaid expenses and other current and non-current assets | 2,720 |
| Accounts receivable | 157 |
| Collaboration receivable - related party | 0 |
| Inventories | 0 |
| Deferred income - related party | 0 |
| Deferred revenue - related party | 0 |
| Accounts payable | -2,397 |
| Accrued liabilities due to spn - related party | 14,472 |
| Operating lease liabilities | -8,674 |
| Accrued expenses and other current and long-term liabilities | -6,508 |
| Net cash provided by (used in) operating activities | 1,117 |
| Purchases of property and equipment | 252 |
| Proceeds from sales of property and equipment | 210 |
| Purchases of investments | 0 |
| Sales and maturities of investments | 0 |
| Sales of restricted investments | 0 |
| Proceeds from sale of vowst business | 0 |
| Net cash (used in) provided by investing activities | -42 |
| Proceeds from at the market equity offering, net of issuance costs | 13,167 |
| Proceeds from exercise of stock options | 501 |
| Proceeds from securities purchase agreement - related party | 0 |
| Issuance of common stock under espp | 230 |
| Proceeds from issuance of debt, net of issuance costs | 0 |
| Repayment of notes payable | 0 |
| Net cash provided by (used in) financing activities | 13,898 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 14,973 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 0 |
| Cash, cash equivalents and restricted cash at beginning of year | 39,461 |
| Cash, cash equivalents and restricted cash at end of year | 54,434 |
Seres Therapeutics, Inc. (MCRB)
Seres Therapeutics, Inc. (MCRB)